IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Phase 3

Completed

• Conditions: Metastatic Renal Cell Carcinoma
• Interventions: Drug: Sunitinib; Biological: GM-CSF; Drug: Cyclophosphamide; Drug: IMA901

• Registration Number: NCT01265901
• Lead Sponsor: Immatics Biotechnologies GmbH

Brief Summary

The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy with sunitinib.

Secondary objectives include a subgroup analysis of overall survival in patients defined by a certain biomarker signature, the investigation of progression-free survival, best tumor response, safety, and immunological parameters.

Detailed Description

This is a multicenter, open-label, randomized phase III study to investigate whether therapeutic vaccination with IMA901, a mult-peptide cancer vaccine (TUMAP), can prolong overall survival in patients with metastatic and/or locally advanced RCC when added to standard first-line therapy with sunitinib (primary endpoint).

Secondary endpoints include a subgroup analysis of overall survival in patients who are positive for a prospectively defined primary biomarker signature (identified as being predictive for improved clinical outcome in IMA901-vaccinated patients in the previous phase II study), progression-free survival (PFS), best overall response, cellular immunomonitoring in a subset of patients, and safety. Safety analysis will be based on adverse events (AEs), physical examinations, vital signs, hematology, clinical chemistry, urinalysis and ECG changes.

Further endpoints include subgroup analyses of overall survival in patients who are positive for further prospectively defined biomarkers (identified in the previous phase II study), and exploratory screening of new biomarkers (to be investigated in patients' blood and paraffin sections from tumor tissue) to predict better clinical outcome as response to vaccination with IMA901. Biomarker sets will not be used for patient selection in this study.

Study Timeline

• Study Start: 2010-12
• Study First Submitted: 2010-12-22
• Study First Submitted QC: 2010-12-22
• Study First Posted: 2010-12-23
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Status Verified: 2017-09
• Disposition First Submitted: 2017-09-25
• Disposition First Submitted QC: 2017-09-28
• Disposition First Posted: 2017-10-04
• Last Update Submitted: 2017-10-04
• Last Update Posted: 2017-10-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 339

Inclusion Criteria

1. Aged at least 18 years.

2. HLA type: HLA-A*02-positive

3. Metastatic and/or locally advanced RCC with clear cell histology (histological confirmation by local pathologist required). NOTE: prior nephrectomy is NOT required.

4. Measurable and/or non-measurable tumor lesions as per RECIST 1.1

5. Patients who are candidates for a first-line therapy with sunitinib.

6. Favorable or intermediate risk according to the 6-score risk criteria in patients treated with VEGF-targeted agents according to Heng [Heng et al. 2009]. The patient has a favorable risk if none, or intermediate risk if one or two of the following criteria apply (if three or more criteria apply the patient is not eligible):

   1. Hemoglobin < LLN,
   2. Serum corrected calcium > ULN,
   3. Karnofsky performance status < 80%,
   4. Time from initial diagnosis to initiation of therapy < 1 year,
   5. Absolute neutrophil count > ULN,
   6. Platelets > ULN.

7. Able to understand the nature of the study and give written informed consent.

8. Willingness and ability to comply with the study protocol for the duration of the study.

9. Female patients who are post menopausal (no menstrual period for a minimum of 1 year), or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or practice a medically acceptable method of birth control.

10. Male patients willing to use contraception (upon study entry and during the course of the study or have undergone vasectomy.

Exclusion Criteria

1. Prior systemic therapy for metastatic disease. (Note: prior adjuvant treatment for non-metastatic disease is allowed, however adjuvant therapy must have been stopped ≥ 1 year before Visit C).

2. History of or current brain metastases.

3. Abnormal ≥ CTC Grade 3 laboratory values for hematology (Hb, WBC, neutrophils, lymphocytes, platelets), liver (serum bilirubin, ALAT or ASAT) and renal function (serum creatinine).

4. Metastatic second malignancy.

5. Localized second malignancy expected to influence the patient's life span.

6. Patients with a history or evidence of systemic autoimmune disease, e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematodes (SLE), scleroderma, Sjögren's syndrome, Wegener's granulomatosis, Guillain-Barre syndrome.

7. Known active hepatitis B or C infection.

8. Known HIV infection.

9. Active infections requiring oral or intravenous antibiotics.

10. Any other known infection with a biological agent that can cause a severe disease and poses a severe danger to lab personnel working on patients' blood or tissue.

11. Received study drug within any clinical study (including approved and experimental drugs) within 4 weeks before sunitinib start.

12. Serious intercurrent illness, which according to the investigator, poses an undue risk for the patient when participating in the trial, including, but not limited to, any of the following:

    • Clinically significant cardiovascular disease (e.g., uncontrolled hypertension; clinically significant cardiac arrhythmia, clinically significant QT-prolongation),
    • New York Heart Association class III-IV congestive heart failure,
    • Symptomatic peripheral vascular disease,
    • Severe pulmonary dysfunction,
    • Psychiatric illness or social situation that would preclude study compliance.

13. Less than 12 months since any of the following:

    • Myocardial infarction,
    • Severe or unstable angina,
    • Coronary or peripheral artery bypass graft,
    • Cerebrovascular event incl. transient ischemic attack,
    • Pulmonary embolism / deep vein thrombosis (DVT).

14. Pregnancy or breastfeeding.

15. Any condition which in the judgment of the investigator would place the patient at undue risk or interfere with the results of the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IMA901 plus GM-CSF added to sunitinib after single dose of cy	GM-CSF	After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
Sunitinib	Sunitinib	Sunitib as Standard therapy per Label.
IMA901 plus GM-CSF added to sunitinib after single dose of cy	Sunitinib	After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
IMA901 plus GM-CSF added to sunitinib after single dose of cy	Cyclophosphamide	After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
IMA901 plus GM-CSF added to sunitinib after single dose of cy	IMA901	After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib

Primary Outcome Measures

Name	Time	Method
Overall survival	2015 (estimated)

Secondary Outcome Measures

Name	Time	Method
Overall survival in biomarker-defined subgroup	2015 (estimated)
Best tumor response	2014 (estimated)
Progression-free survival	2014 (estimated)
Safety and tolerability	continuously
Cellular immunomonitoring	2014 (estimated)

Trial Locations

Locations (105)

University of Arkansas for Medical Sciences; 🇺🇸 Little Rock, Arkansas, United States

Cedars-Siani Medical Center, Samuel Oschin Comprehensive Cancer Institute; 🇺🇸 Los Angeles, California, United States

Kaiser Permanente Oncology Hematology Clinic; 🇺🇸 Denver, Colorado, United States

Georgetown University Medical Center, Lombardi Comprehensive Cancer Center; 🇺🇸 Washington, D.C., District of Columbia, United States

M.D. Anderson Cancer Center; 🇺🇸 Orlando, Florida, United States

The University of Chicago Medicine; 🇺🇸 Chicago, Illinois, United States

North Central Cancer Treatment Group, Illinois Cancer Care; 🇺🇸 Peoria, Illinois, United States

IU Simon Cancer Center; 🇺🇸 Indianapolis, Indiana, United States

Weinberg Cancer Institute at Franklin Hospital; 🇺🇸 Baltimore, Maryland, United States

Karmanos Cancer Institute; 🇺🇸 Detroit, Michigan, United States

Scroll for more (95 remaining)